[Effects of oral flecainide treatment of refractory tachyarrhythmias].
Oral flecainide treatment was given to five patients who were refractory to conventional antiarrhythmic agents. The five patients included one with atrioventricular reentrant tachycardia (AVRT), one with non-sustained ventricular tachycardia (nsVT) and three with sustained VT (sVT). Flecainide produced favorable responses in patients of AVRT, nsVT and sVT with arrhythmogenic right ventricular dysplasia (ARVD). In the case of AVRT, flecainide exhibited a preventive effect on tachycardia induced by programmed electrical stimulation (PES). In the case of nsVT, flecainide markedly reduced the number of VPC and abolished the VT on the Holter ECG. In the case of sVT with ARVD, sVT was not induced by PES after the flecainide. Long-term treatment with flecainide on these three cases produced complete prevention of tachycardias. As an adverse effect of flecainide, an aggravation of congestive heart failure was recognized in one case with cardiac sarcoidosis. PQ interval and QRS interval in all the cases were prolonged after flecainide. The results indicate that flecainide is a useful antiarrhythmic agent for tachyarrhythmias refractory to treatment with conventional drugs.
Sakurada
H
H
Department of Cardiology, Tokyo Metropolitan Hiroo General Hospital.
Hiyoshi
Y
Y
Tejima
T
T
Yanase
O
O
Tokuyasu
Y
Y
Watanabe
K
K
Motomiya
T
T
Sugiura
M
M
Hiraoka
M
M
D000284:Administration, Oral; D000328:Adult; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D004341:Drug Evaluation; D004562:Electrocardiography; D005260:Female; D005424:Flecainide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male
D005424:Flecainide